AtriCure, Inc.(ATRC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #962 of 2,960 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ATRC Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for AtriCure, Inc. (ATRC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATRC at 59.0/100 on a 32-signal composite quality model, placing it at rank #962 of 2,960 stocks — the top half of the AI-ranked universe. ATRC scores in the top quartile across earnings quality (97.4). Areas of concern include revenue scale (38.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AtriCure, Inc. reports quarterly revenue of $153.6M, net income of $9.0M, an operating margin of 6.3%. Top institutional holders of ATRC by reported 13-F value include BlackRock, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ATRC trades on the Nasdaq exchange and files with the SEC under CIK 1323885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATRC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AtriCure, Inc. directly from SEC EDGAR. AtriCure, Inc.'s 13F Pro composite quality score has ranged between 28 and 59 since 2021, currently 59.0 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.
Revenue
Q2 2026
$153.6M
Net Income
Q2 2026
$9.0M
Free Cash Flow
Q2 2026
$18.4M
Operating Margin
Q2 2026
6.3%
ROIC
Q2 2026
6.7%
D/E Ratio
Q2 2026
0.12
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+14.9% YoYNet Income
+74.4% YoYOperating Income
+76.4% YoYEPS (Diluted)
+74.7% YoYTotal Assets
+7.4% YoYTotal Debt
-4.3% YoYOp. Cash Flow
+369.8% YoYFree Cash Flow
+6381.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $534.5M +14.9% | $465.3M +16.5% | $399.2M +20.8% | $330.4M +20.4% | $274.3M +32.8% | $206.5M |
| Net Income | $-11.4M +74.4% | $-44.7M -46.8% | $-30.4M +34.5% | $-46.5M -192.6% | $50.2M +204.2% | $-48.2M |
| Operating Income | $-9.4M +76.4% | $-40.0M -50.0% | $-26.7M +37.5% | $-42.7M -177.3% | $55.2M +224.8% | $-44.2M |
| EPS (Diluted) | $-0.24 +74.7% | $-0.95 -43.9% | $-0.66 +35.3% | $-1.02 -193.6% | $1.09 +195.6% | $-1.14 |
| Total Assets | $654.2M +7.4% | $609.3M -0.7% | $613.9M +4.9% | $585.4M -4.9% | $615.3M -13.9% | $714.5M |
| Total Debt | $61.9M -4.3% | $64.7M +1.8% | $63.5M -3.0% | $65.5M +9.1% | $60.0M -10.0% | $66.7M |
| Operating Cash Flow | $57.3M +369.8% | $12.2M +172.2% | $4.5M +120.3% | $-22.1M -60.7% | $-13.8M +30.6% | $-19.9M |
| Free Cash Flow | $48.3M +6381.1% | $745.0K +109.9% | $-7.5M +80.7% | $-39.0M -65.8% | $-23.5M +6.3% | $-25.1M |
Get alerted when ATRC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AtriCure, Inc. including:
Top Institutional Holders of ATRC
BlackRock, Inc.
$125.2M4,474,548 shWELLINGTON MANAGEMENT GROUP LLP
$97.8M3,495,603 shVANGUARD PORTFOLIO MANAGEMENT LLC
$87.5M3,127,195 shHood River Capital Management LLC
$81.3M2,905,299 shALLIANCEBERNSTEIN L.P.
$79.0M2,768,365 shVANGUARD CAPITAL MANAGEMENT LLC
$61.3M2,190,413 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$48.5M1,734,279 shGOLDMAN SACHS GROUP INC
$44.7M1,597,988 shSTATE STREET CORP
$38.9M1,389,989 shMARSHALL WACE, LLP
$37.3M1,333,904 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $125.2M | 4,474,548 |
| WELLINGTON MANAGEMENT GROUP LLP | $97.8M | 3,495,603 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $87.5M | 3,127,195 |
| Hood River Capital Management LLC | $81.3M | 2,905,299 |
| ALLIANCEBERNSTEIN L.P. | $79.0M | 2,768,365 |
| VANGUARD CAPITAL MANAGEMENT LLC | $61.3M | 2,190,413 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $48.5M | 1,734,279 |
| GOLDMAN SACHS GROUP INC | $44.7M | 1,597,988 |
| STATE STREET CORP | $38.9M | 1,389,989 |
| MARSHALL WACE, LLP | $37.3M | 1,333,904 |
Companies Similar to ATRC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Axogen, Inc.
SI-BONE, Inc.
Xeris Biopharma Holdings, Inc.
KORU Medical Systems, Inc.
REPLIGEN CORP
LifeStance Health Group, Inc.
Cadre Holdings, Inc.
iRhythm Holdings, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ATRC on your watchlist
Track score changes the day AtriCure, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ATRC a good stock to buy?
13F Pro's AI-powered analysis of AtriCure, Inc. (ATRC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATRC are available on the ATRC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ATRC is classified as a mid company.
Which hedge funds own ATRC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATRC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AtriCure, Inc.'s investment landscape.